Contact Us | News | Site Map
Aridis Pharmaceuticals © 2010 Le3 Web Designs
News
Januray 8 th, 2010
Aridis out-
September 30th, 2009
Aridis awarded National Institute of Health grant award to develop new generation
of anthrax vaccine.
July 17th, 2009
Aridis awarded SBIR Award from the National Institute of Allergy and Infectious
Diseases, NIH to develop inhalable gallium based therapeutics.
January 9th, 2009
Aridis awarded U.S. Agency for International Development (USAID) award in collaboration
with Mapp BioPharmaceutical to develop microbicides monoclonal antibodies.
September 26th, 2008
Aridis awarded two technology development grants to develop stabilization technologies
for F. tulerensis and filovirus vaccines.
February 19th, 2008
Aridis completed an agreement with the University of Iowa Research Foundation
for exclusive worldwide rights to gallium based anti-
July 15th, 2007
The National Institutes of Health awarded Aridis and Harvard University with
an NIH STTR grant for preclinical development of human monoclonal antibody (AerucinTM)
for the treatment of Pseudomonas aeruginosa infetions. More...
June 1st, 2007
Aridis entered into a formulation development agreement with a nonprofit organization
PATH to collaborate on the development of select rotavirus vaccine formulations.
This agreement is for a three year period and Aridis will be reimbursed for expenses
incurred up to a total of about $1.9 M.
July 10th, 2007
Enwave Corporation and Aridis are working to establish the feasibility of formulating
room temperature stable vaccines and antibodies using the EnWave’s bioREV microwave
assisted vacuum drying technology. Aridis is reimbursed for expenses.
May 15th, 2007
Aridis' collaboration with Johns Hopkins University on oral thin film delivery systems for vaccines featured in Newsweek and Fox News.
